Patient Card

LUXTURNA®
voretigene neparvovec
for subretinal injection

Patient name: .....

	TREATED EYE	
	☐ Left eye	☐ Right eye
Date of treatment		
LUXTURNA® batch number		

Treating ophthalmologist

Name: .....

Phone number: .....

This material has been created and funded by Novartis.
Approved by MHRA 01/2024

UK | January 2024 | 373164

NOVARTIS

Information for patients:

Ensure that you attend all follow-up appointments and if you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack. The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects. The information on this card is available as a credit card format and an audio file and can be found at https://www.medicines.org.uk/emc/product/9856.

Information for healthcare professionals:

The holder of this card has received LUXTURNA®▼ (voretigene neparvovec), an adeno-associated virus vector based gene therapy. Before providing any treatment, please call their prescribing physician on the number provided on this card. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report.

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com.